Tislelizumab Plus Platinum-Based Chemotherapy as First-Line Treatment for Advanced Lung Cancer with KRAS Mutation in China

In China KRAS mutations are infrequent driver mutations in lung cancer and confer a poor prognosis. The inhibitors AMG 510 and MRTX849 targeting the KRAS G12C mutation had shown promising results in clinical trials. However, KRAS G12C inhibitors are approved for second-line treatment of advanced NSCLC and unavailable in Chinese patients. Tislelizumab (tis), an anti-PD-1 mAb, had shown improved efficacy when combined with chemotherapy in pts with advanced EGFR-wt NSCLC. This study aims to evaluate the efficacy and safety of tis plus chemotherapy in Chinese patients with KRAS-mut lung cancer.